# A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis

> **NCT02469467** · PHASE1,PHASE2 · UNKNOWN · sponsor: **KDL Inc.** · enrollment: 30 (estimated)

## Conditions studied

- End Stage Renal Disease
- Hyperphosphatemia

## Interventions

- **DIETARY_SUPPLEMENT:** VS-505

## Key facts

- **NCT ID:** NCT02469467
- **Lead sponsor:** KDL Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2016-10
- **Final completion:** 2016-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02469467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02469467, "A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02469467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*